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Summary
The forthcoming National Institute for Health and Care
Excellence depression guideline reviews short-term outcomes
for long-term depression. We present effect sizes for long-term
outcomes in trials that report these data. Psychological therapies
become more effective, whereas antidepressants become
less effective over the long term. We review other forms of
longitudinal research that support these findings.
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The National Institute for Health and Care Excellence (NICE) have
compiled and synthesised a large collection of randomised con-
trolled trials on depression for the forthcoming guideline update.1
Trials on long-term forms of depression are grouped into chronic
depression and treatment-resistant depression (TRD). Chronic
depression trial populations (defined as an episode of at least
2 years) have an actual range of 26–348 months duration.1 TRD
trial populations have episodes ranging from 0.4 to 92 months;
60% of TRD studies report mean episodes of 2 years or more.1
Long-term outcomes in these trials have not been analysed; the
review only uses end-of-treatment outcomes, which vary from
1 to 78 weeks, with an average of around 10 weeks. The rationale
given is that there are not enough studies with long-term data to
analyse.2 Stakeholders have argued that long-term outcomes
provide the ‘best-possible evidence’ and NICE executives have
recently agreed to look at the issue again.3 We examine available
data to illustrate how NICE could make use of this evidence.
Although NICE and other commentators consider TRD and
chronic depression to be distinct categories of depression, it has
been argued that when subclassified based on limited information
available from trials reviewed by NICE, these are not clinically
meaningful distinctions.4 Specifically, based on the information
both present and, critically, absent in the trial papers, there is no
reliable basis on which to suppose that these populations are not
overlapping. We therefore examine both categories for the purposes
of the current commentary.
In chronic depression and TRD categories, 124 trials were
included.1 Ninety-eight of these included an antidepressant arm
(as defined by NICE), 30 included a psychological treatment
arm and a proportion of these had both antidepressant and
psychological treatment groups. Twenty-two had observation
points of 6 months or more. Of these, there were 11 in which
the 6-month observation was at end of treatment, rather than
‘follow-up’. Without a period between end of treatment and
follow-up, it is not possible to form a view on whether the
effects of the treatment last beyond end of treatment. Table 1 col-
lates information for the remaining 11 trials: we report the amount
of change on continuous symptom scales at end of treatment and
follow-up for each of the trials with long-term follow-up data via
Cohen’s d effect sizes. Trials are ordered by group comparison
effect size at follow-up.
Time between end of treatment and follow-up ranged from
18 to 104 weeks, which limits comparability. In addition, in the
smaller studies, the confidence intervals were quite wide, which
limits the degree of certainty in the findings. However, examining
pre–post effect sizes by intervention arm indicates that most psy-
chological treatments for both TRD and chronic depression
appear to become more effective at follow-up, with the exception
of cognitive interpersonal group psychotherapy, which appears to
become less effective, and cognitive–behavioural analysis system
of psychotherapy, which has mixed results. The latter two psycho-
logical treatments were examined in populations classified by
NICE as chronic depression. Examining group comparison effect
sizes at follow-up suggests that antidepressants are consistently
less effective than either psychological treatment alone or in
combination with antidepressants over the long term.
There are limitations to comparing antidepressant and psycho-
logical treatment trials, which apply to all the trials reviewed, includ-
ing inflation of outcomes from different comparator arms (only two
of the trials directly compared antidepressants alone with psycho-
logical treatment alone); effects of completer versus intention-to-
treat (ITT) analyses (half of the trials here used ITT or modified
ITT requiring a minimum of one session attendance); inflation of
effects from non-blinding in psychological treatments; and differen-
tial effects of under-reporting harms, side-effects and tolerability in
psychological treatment versus antidepressant trials. Therefore, the
findings here are not presented as a standalone meta-analysis
and should be interpreted with caution. NICE guidelines provide
grading of recommendations assessment, development and evalu-
ation (GRADE) of all trials to take these sorts of bias into account
when translating findings into recommendations. Although the
draft depression guideline has produced preliminary GRADE
assessments, these cannot yet be directly applied to the current ana-
lysis because they remain under review and stakeholders have raised
significant concerns about the way in which GRADE was applied.2
Of particular relevance to the current analysis is the concern that
trials were downrated on quality if the 95% confidence interval
crossed both line of no effect and threshold for clinically important
benefit at the end of treatment, irrespective of whether this had
ceased to be the case at a follow-up data point, which
stakeholders argue prejudices trials where the effect emerges at
follow-up. Also relevant is the concern that trials were downrated
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Table 1 Effect sizes at end of treatment and follow-up
Study24–34
Classification in
NICE guideline
Current episode
duration (mean
months, s.d.) Na
Measure for
effect sizeb
Treatment
duration
(weeks)
Follow-up
(weeks from
baseline)
Effect size (end of treatment) Effect size (follow-up)
Baseline to endc (95% CI)
Group
comparisond Baseline to follow-upc (95% CI) Group comparisonc
Paykel 1999 TRD 13.8 (median) 158 20 68 Cognitive therapy plus ADM:
NDA
ADM: NDA
NDA Cognitive therapy plus ADM:
NDA
ADM: NDA
NDA
Valenstein 2015 TRD Not reported 334 BDI-II 24 52 Peer support: 0.59 (0.33–0.85)
TAU: 0.62 (0.43–0.80)
−0.03 Peer support: 0.72 (0.46–0.98)
TAU: 0.71 (0.52–0.90)
0.01
Hellerstein 2001e Chronic depression Not reported 32 HRSD 16 36 CIGP + ADM: 0.19 (−0.45 to 0.83)
ADM: 0.13 (−0.52 to 0.79)
0.06 CIGP + ADM: −0.07 (−0.71 to
0.56)
ADM: −0.02 (−0.68 to 0.63)
0.05
Browne 2002e Chronic depression Not reported 586 MADRS 26 104 IPT: 1.28 (1.06–1.49)
IPT + ADM: 1.28 (1.07–1.49)
ADM: 0.92 (0.70–1.14)
IPT versus
ADM: 0.36
NDA IPT versus ADM:
0.27
Wiles 2013e TRD Not reported 408 BDI-II 27 52 CBT + ADM: 1.04 (0.84–1.24)
ADM: 0.61 (0.42–0.80)
0.43 CBT + ADM: 1.21 (1.00–1.42)
ADM: 0.85 (0.65–1.05)
0.36
Schramm 2011e Chronic depression 243.6 (135.6) 29 BDI-II 16 52 CBASP: 1.64 (0.78–2.49)
IPT: 0.61 (−0.13 to 1.34)
0.87 CBASP: 1.17 (0.37–1.97)
IPT: 0.83 (−0.08 to 1.58)
0.43
Schramm 2015e Chronic depression Not reported 59 MADRS 8 28 CBASP: 0.42
ADM: 0.63
−0.21 CBASP: 0.98
ADM: 0.50
0.48
Fonagy 2015e TRD 45.0 (36.4) 129 HRSD 78 182 LTPP: 0.60 (0.25–0.95)
TAU: 0.40 (0.05–0.76)
0.20 LTPP: 0.65 (0.30–1.00)
TAU: 0.02 (−0.33 to 0.37)
0.63
Chiesa 2015e TRD 25.5 (47.9) 43 HRSD 8 26 GMBCT + ADM: 1.12 (0.50–1.74)
Psychoeducation plus ADM:
0.29 (0.33–0.92)
0.83 GMBCT + ADM: 1.54 (0.88–2.20)
Psychoeducation plus ADM:
0.39 (0.23–1.02)
1.15
de Mello 2001 Chronic depression Not reported 23 HRSD 12 48 IPT + ADM: 2.84 (1.76–3.19)
ADM: 2.65 (1.69–3.60)
0.19 IPT + ADM: 3.67 (2.43–4.91)
ADM: 2.46 (1.51–3.40)
1.21
Schramm 2008 Chronic depression Not reported 37 HRSD 5 52 IPT + ADM: 2.56 (1.80–3.32)
ADM: 1.44 (0.76–2.12)
1.12 IPT + ADM: 4.19 (3.12–5.28)
ADM: 1.52 (0.81–2.22)
2.67
NICE, National Institute for Health and Care Excellence; TRD, treatment-resistant depression; ADM, anti-depressant medication; NDA, no data available (missing means and/or s.d. to allow calculation); BDI-II, Beck Depression Inventory-II; TAU, treatment as usual; HRSD,
Hamilton Rating Scale for Depression; CIGP, cognitive interpersonal group psychotherapy; MADRS, Montgomery–Asberg Depression Rating Scale; IPT, interpersonal therapy; CBT, cognitive–behavioural therapy; CBASP, cognitive–behavioural analysis system of psychotherapy;
LTPP, long-term psychodynamic psychotherapy; GMBCT, group mindfulness base cognitive therapy.
For detailed information about measures and references, see the full guideline updated version.1
a. Number at last time point.
b. Measures selected based on what data were available at the follow-up point.
c. Effect sizes reported are Cohen’s d calculated from raw mean and s.d. weighted by sample size (except Schramm 2015 where the author provided effect size for end follow-up are used and hence no confidence interval is reported).
d. Group comparison effect size calculated as effect size 1 minus effect size 2 (except Browne 2002 baseline follow-up, which is calculated from author reported change scores).
e. Intention-to-treat analysis (ITT) or modified ITT (participants who attended a minimum of one session).
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on quality where participants were not blinded; stakeholders argue
this systematically prejudices psychological treatment trials in
which concealment of the treatment arm is impossible.
Although it remains necessary to be cautious about the tentative
findings presented, it is also possible to consider other forms of lon-
gitudinal data that appear to support the findings. Discontinuation
trials, for example, were designed to test the efficacy of staying on
antidepressants long-term compared with stopping and switching
to placebo. About a third of patients remaining on antidepressants
relapse within 6 months of maintenance therapy.5 Remaining on
antidepressants for more than 18 months appears to prevent imme-
diate relapse but, when antidepressants are then discontinued,
recurrence is very common. Indeed, recurrence is more likely the
longer the antidepressant has been taken and is more likely
for patients using antidepressants than for trial participants who
remitted while on placebo.6,7 These findings could be a result of
‘oppositional tolerance’ or neurobiological adaptation to antide-
pressants worsening the long-term course of depression.8 The
picture is further complicated, however, because any trial examining
‘relapse’ as an outcome of stopping antidepressants could be
conflating relapse with withdrawal symptoms.9
Various naturalistic cohort studies show that long-term anti-
depressant use has worse outcomes than short-term antidepressant
use or non-pharmacological treatments.10,11 Moreover, it appears to
be difficult to stop antidepressants after extended use;12 some
patients using antidepressants may develop dependency13 and
patients using antidepressants long term report feeling addicted.14
Safety reviews find that long-term antidepressant use is associated
with serious health risks, including obesity, hepatotoxicity and
cardiovascular events.8
Meta-analyses of direct comparisons in randomised controlled
trials for (recurrent) major depressive disorder (MDD) consistently
show that, in protecting against relapse in the long term, psycho-
logical treatment is superior to maintenance antidepressant use.15
In combination for up to 6 months, antidepressants plus psycho-
logical treatment appears to be more effective for MDD than psy-
chological treatment or antidepressants alone; however, long-term
follow-ups reveal that beyond 6 months, there is no advantage of
combination treatment over psychological treatment alone.16 Two
reviews also found that (mindfulness-based) cognitive–behavioural
therapy following antidepressant discontinuation was more effect-
ive than antidepressant continuation.17,18
Treatment comparison studies suggest that long-term psycho-
logical treatment irrespective of modality generates large effect
sizes over the long term for MDD and chronic depression. For
example, comparisons of cognitive–behavioural therapy and psy-
choanalytic psychotherapy find roughly equal but strong effect
sizes after 1 year19 and 3 years.20 Similarly, a systematic review
found that long-term relapse rates in depression over 2 years are
lower for psychological treatments than other interventions.21 In
contrast, less than 10% of patients treated with antidepressants
achieve sustained remission over 1 year in representative real-
world effectiveness trials.22 A systematic review of naturalistic
studies of antidepressant use of at least 10 years’ duration revealed
that only about a quarter of people improved or remitted, and
another quarter were classified as severely impaired and ill-
functioning.23
Conclusion
If it is possible to agree that good-quality, long-term trial data is the
best possible evidence for long-term conditions, then the paucity
and variable quality of this data should not be a reason to exclude
it in analyses used to inform depression guideline
recommendations. Tentative analyses of long-term outcome data
reveal an important clinical picture, which is supported by evidence
from other forms of longitudinal research. Although the evidence
remains to be appropriately evaluated with GRADE methodology,
it is nevertheless important to consider it in the guideline because
of the effect NICE guidelines have globally on patient care as well
as ongoing and future research priorities.
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Data availability
Sources of information used were NICE guideline drafts, documents and appendices all
available on the NICE website.1 Specifically, Appendix J5 and J6 were used, which detail all
trials reviewed in the TRD and chronic depression categories. See https://www.nice.org.uk/
guidance/gid-cgwave0725/documents/addendum-appendix-9 and https://www.nice.org.uk/
guidance/gid-cgwave0725/documents/addendum-appendix-10. Note that Town 2017 was
included in the ‘Full guideline updated’ but omitted from Appendix J5.
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